Overview
From Risk Assessment to Treatment: Real-World Approaches to PAH
Expert Commentary
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this clinical commentary, join cardiology expert Dr. Vallerie McLaughlin, Director of the Pulmonary Hypertension Program at the University of Michigan and pulmonology expert Dr. Victor Tapson, Director, Pulmonary Vascular Disease Research at Cedars-Sinai Medical Center as they provide real-world advice on the management of pulmonary arterial hypertension (PAH). These experts will discuss their best practices for:
• Risk assessment and stratification
• Use of oral combination therapies
• Management of PAH patients during COVID-19
• Risk assessment and stratification
• Use of oral combination therapies
• Management of PAH patients during COVID-19
Dr. McLaughlin and Dr. Tapson also provide their insights into the future of PAH management, with a discussion of emerging therapeutic options.
This activity is intended for pulmonologists, cardiologists, cardiopulmonologists, and other healthcare providers (MDs, PAs, and NPs) interested in treating patients with PAH.
Treatment selection for patients with pulmonary arterial hypertension (PAH) is complex, when considering the number of therapies, combinations of different therapies, and recent updates to treatment guidelines. Clinicians require ongoing education on the most recent guideline recommendations and treatment algorithms, and how to apply these recommendations in their practices. Clinicians will learn best practices for risk assessment and treatment of PAH to increase competency of PAH management, and will learn about the management of PAH patients during COVID-19. Upon completion of this activity, clinicians will be better able to apply treatment algorithms and risk assessment to improve PAH patient care.
Upon completion of this activity, participants will be able to:
• Evaluate current real-world practices for the management of PAH with combination therapy and within the context of COVID-19
• Review recent clinical data that inform the safety and efficacy of individual PAH treatments and combination therapies
• Discuss emerging clinical research initiatives in PAH and their potential impact on both current and future patient care plans
• Evaluate current real-world practices for the management of PAH with combination therapy and within the context of COVID-19
• Review recent clinical data that inform the safety and efficacy of individual PAH treatments and combination therapies
• Discuss emerging clinical research initiatives in PAH and their potential impact on both current and future patient care plans
• 2019 Recommendations From the 6th World Symposium on Pulmonary Hypertension and CHEST Guidelines
• Impactful Publications From 2020
• Experiences With Combination Therapy in Clinical Practice
• COVID-19 and PAH
• Emerging Treatments for PAH
• Impactful Publications From 2020
• Experiences With Combination Therapy in Clinical Practice
• COVID-19 and PAH
• Emerging Treatments for PAH
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Vallerie McLaughlin, MD
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI
Victor Tapson, MD
Professor of Medicine
Director, Venous Thromboembolism Research
Director, Clinical Research, Women’s Guild Lung Institute
Associate Director, Division of Pulmonary and Critical Care
Director, Pulmonary Vascular Disease Research
Cedars-Sinai Medical Center
Los Angeles, CA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Vallerie McLaughlin, MD (Faculty)
Consultant (Retained): Acceleron Pharma, Inc., Actelion Pharmaceuticals US, Inc., Altavant Sciences, Inc., Caremark, CiVi Biopharma, Inc., Gossamer Bio, Liquidia, United Therapeutics
Grant/Research Support Recipient: Acceleron Pharma, Inc., Actelion Pharmaceuticals US, Inc., Gilead Sciences, Inc., Reata Pharmaceuticals Inc., SonoVie, United Therapeutics
Victor Tapson, MD, (Faculty)
Advisor or Review Panel Member: Bristol Myers Squibb, Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Occasional): Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Retained): Thrombolex, Inc. and V-Wave Ltd.
Grant/Research Support Recipient: Bristol Myers Squibb, Eli Lilly and Company, Genentech, United Therapeutics, Verily Life Sciences
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Sotatercept for the management of PAH
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
